Akers Biosciences, Inc. 'ABI' or the 'Company' Receipt of Further United States Military Contracts

Tuesday, September 18, 2007 General News
Email Print This Page Comment
THOROFARE, N.J., Sept. 17 Akers Biosciences,Inc. (LSE: AKR) which develops, manufactures, and supplies rapid, point ofcare screening and testing products, is pleased to announce that it hasreceived an order from the United States Army for the purchase of itsBreathScan alcohol safety units. This contract is valued at $2,500,000 and isdeliverable beginning immediately.

The Company has previously stated that it had expected significant ordersfrom several departments of the United States Government as a result of its'efforts to increase safety awareness. ABI continues to anticipate such furtherorders in the near future. The units provided consist of the Company's unique,patented disposable breathalyzer device housed within its patented, portableand refillable key ring case.

Thomas A. Nicolette, President and CFO of ABI, commented, "This latestorder will take the total number of our BreathScan alcohol safety units in useby the US Military to over 950,000. This is the beginning of a recurringrevenue business model generated from this product line, where the alcoholbreathalyzers will continually require replacement as they are used anddisposed of. We confidently expect other divisions of the United StatesMilitary to introduce our product line over the course of the very nearfuture.

This is the clearest progressive step to date in transforming ABI from apurely research and development company to business that is capitalizing onits proprietary product lines and generating sustainable revenues from them."

Akers Biosciences

Akers Biosciences, Inc. develops, manufactures, and supplies rapid, pointof care screening and testing products designed to bring healthcareinformation both rapidly and directly to the patient or healthcare provider.The Company has advanced the science of diagnostics while responding to majorshifts in healthcare through the development of several proprietary platformtechnologies. The company's state-of-the-art rapid diagnostic assays can beperformed virtually anywhere in minutes when time is of the essence. Akers hasaligned with major healthcare companies and high volume medical productsdistributors to maximize product offerings, and to be a major worldwidecompetitor in diagnostics. Additional information on the Company and itsproducts can be found at www.akersbiosciences.com.Contact: Akers Biosciences, Inc. Thomas A. Nicolette, President & CFO Tel (856) 848-8698

SOURCE Akers Biosciences, Inc.


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook